Business Description
Vivoryon Therapeutics N.V. is a German clinical-stage company developing small molecule drugs to treat Alzheimer's disease, with its leading candidate PQ912 having already completed mid-stage clinical trials. The company targets a harmful protein fragment linked to Alzheimer's progression and is also working on an antibody-based therapy addressing the same pathway. Vivoryon works alongside partners including Nordic Bioscience, the Fraunhofer Institute, and Simcere Pharmaceutical Group to advance and commercialize its treatments across global markets.
